文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Toon S, Holt B L, Mullins F G, Bullingham R, Aarons L, Rowland M

Department of Pharmacy, University of Manchester.

Br J Clin Pharmacol. 1990 Nov;30(5):743-50. doi: 10.1111/j.1365-2125.1990.tb03845.x.

The potential interaction between racemic warfarin given as a 25 mg single oral dose and chronically administered ketorolac was studied in 12 young healthy male volunteers. 2. Ketorolac produced no major change in the pharmacokinetics of (R)- or (S)-warfarin. 3. Ketorolac did not alter the pharmacodynamic profile of racemic warfarin. 4. Ketorolac increased template bleeding time by a factor of 1.35 as compared with placebo. 5. The results suggest that the ketorolac-warfarin interaction is unlikely to be of major clinical significance; however, combined use of ketorolac and warfarin in patients should be undertaken with due caution and appropriate monitoring.

在12名年轻健康男性志愿者中研究了单次口服25毫克消旋华法林与长期服用酮咯酸之间的潜在相互作用。2. 酮咯酸对（R）-或（S）-华法林的药代动力学没有产生重大改变。3. 酮咯酸没有改变消旋华法林的药效学特征。4. 与安慰剂相比，酮咯酸使标准出血时间延长了1.35倍。5. 结果表明，酮咯酸-华法林相互作用不太可能具有重大临床意义；然而，在患者中联合使用酮咯酸和华法林时应谨慎行事并进行适当监测。

Toon S, Holt B L, Mullins F G, Bullingham R, Aarons L, Rowland M

Department of Pharmacy, University of Manchester.

Br J Clin Pharmacol. 1990 Nov;30(5):743-50. doi: 10.1111/j.1365-2125.1990.tb03845.x.

The potential interaction between racemic warfarin given as a 25 mg single oral dose and chronically administered ketorolac was studied in 12 young healthy male volunteers. 2. Ketorolac produced no major change in the pharmacokinetics of (R)- or (S)-warfarin. 3. Ketorolac did not alter the pharmacodynamic profile of racemic warfarin. 4. Ketorolac increased template bleeding time by a factor of 1.35 as compared with placebo. 5. The results suggest that the ketorolac-warfarin interaction is unlikely to be of major clinical significance; however, combined use of ketorolac and warfarin in patients should be undertaken with due caution and appropriate monitoring.

在12名年轻健康男性志愿者中研究了单次口服25毫克消旋华法林与长期服用酮咯酸之间的潜在相互作用。2. 酮咯酸对（R）-或（S）-华法林的药代动力学没有产生重大改变。3. 酮咯酸没有改变消旋华法林的药效学特征。4. 与安慰剂相比，酮咯酸使标准出血时间延长了1.35倍。5. 结果表明，酮咯酸-华法林相互作用不太可能具有重大临床意义；然而，在患者中联合使用酮咯酸和华法林时应谨慎行事并进行适当监测。